Home » Market News » DirectorsTalk Highlights » INTERVIEW: Avacta Group plc First-time-in-human clinical trials
Avacta Group Plc

INTERVIEW: Avacta Group plc First-time-in-human clinical trials

Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the selection of its first-time-in-human clinical candidate for the Affimer platform. Alastair explains the significance of this news, the long term plan for developing immunotherapies with a PDL1 inhibitor and with the announcement that the TMAC linker is going to be tested in humans in the first half of next year which is much sooner than was expected talks us through the planned clinical trial.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.